All In Biotech

NDA 215272 · Organon LLC

Vtama

Tapinarof · Topical · Aryl Hydrocarbon Receptor Agonist

Novel

CDER novel approval, May 23, 2022: To treat plaque psoriasis

Last checked: Nov 20, 2026Latest source record: Dec 12, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2022

May 23, 2022

Approved uses

2

Original approval plus efficacy supplements

Registered trials

29

11 Phase 3, 0 recruiting

FAERS reports

1,974

205 serious, 6 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect May 28, 2025.

VTAMA cream, 1% is an aryl hydrocarbon receptor agonist indicated for: the topical treatment of plaque psoriasis in adults. ( 1.1 ) the topical treatment of atopic dermatitis in adults and pediatric patients 2 years of age and older. ( 1.2 ) 1.1 Plaque Psoriasis VTAMA ® cream is indicated for the topical treatment of plaque psoriasis in adults. 1.2 Atopic Dermatitis VTAMA cream is indicated for the topical treatment of atopic dermatitis in adults and pediatric patients 2 years of age and older.

Mechanism: Tapinarof is an aryl hydrocarbon receptor (AhR) agonist. The specific mechanisms by which VTAMA cream exerts its therapeutic actions are unknown.

Therapeutic areas: Immunology and inflammation

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • VTAMA · TAPINAROF 1% · CREAM, TOPICAL · Prescription · TE TBD

Clinical trials

Interventional ClinicalTrials.gov studies with "Tapinarof" as an intervention, any sponsor and status, largest first.

All 29 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • folliculitis292
  • pruritus238
  • headache182
  • rash152
  • dermatitis contact134
  • drug ineffective130
  • erythema124
  • skin burning sensation87
  • psoriasis77
  • application site erythema63
  • off label use63
  • application site pruritus62

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20191
20203
20214
2022192
2023664
2024506
2025263
2026341

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Vtama (Tapinarof)

2024 spending

$26.7M

Beneficiaries

8,600

18,599 claims

Per beneficiary

$3,107

$23.01 per unit

View as table
YearSpending
2020$0
2021$0
2022$2,800,009
2023$18,812,197
2024$26,721,943

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 31 on PubMed

Sponsor: Organon LLC

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.